152 related articles for article (PubMed ID: 34017087)
1. TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma.
Casey DL; Pitter KL; Wexler LH; Slotkin EK; Gupta GP; Wolden SL
Br J Cancer; 2021 Aug; 125(4):576-581. PubMed ID: 34017087
[TBL] [Abstract][Full Text] [Related]
2. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
4. Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.
Casey DL; Wexler LH; Pitter KL; Samstein RM; Slotkin EK; Wolden SL
Clin Cancer Res; 2020 Mar; 26(5):1135-1140. PubMed ID: 31699828
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Tirode F; Surdez D; Ma X; Parker M; Le Deley MC; Bahrami A; Zhang Z; Lapouble E; Grossetête-Lalami S; Rusch M; Reynaud S; Rio-Frio T; Hedlund E; Wu G; Chen X; Pierron G; Oberlin O; Zaidi S; Lemmon G; Gupta P; Vadodaria B; Easton J; Gut M; Ding L; Mardis ER; Wilson RK; Shurtleff S; Laurence V; Michon J; Marec-Bérard P; Gut I; Downing J; Dyer M; Zhang J; Delattre O;
Cancer Discov; 2014 Nov; 4(11):1342-53. PubMed ID: 25223734
[TBL] [Abstract][Full Text] [Related]
6. Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma.
Casey DL; Wexler LH; Meyers PA; Magnan H; Chou AJ; Wolden SL
Pediatr Blood Cancer; 2015 Mar; 62(3):445-9. PubMed ID: 25346208
[TBL] [Abstract][Full Text] [Related]
7. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines.
Taylor AC; Shu L; Danks MK; Poquette CA; Shetty S; Thayer MJ; Houghton PJ; Harris LC
Med Pediatr Oncol; 2000 Aug; 35(2):96-103. PubMed ID: 10918230
[TBL] [Abstract][Full Text] [Related]
8. Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.
Aryee DN; Niedan S; Ban J; Schwentner R; Muehlbacher K; Kauer M; Kofler R; Kovar H
Br J Cancer; 2013 Nov; 109(10):2696-704. PubMed ID: 24129240
[TBL] [Abstract][Full Text] [Related]
9. Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.
Chen H; Huang H; Zhao J; Wang Z; Chang M; Xue L; Zhu W; Chai Y; Li G; Wang Z; Wu H
J Neurooncol; 2019 Jul; 143(3):369-379. PubMed ID: 31049827
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification by somatic mutation burden in Ewing sarcoma.
Liu KX; Lamba N; Hwang WL; Niemierko A; DuBois SG; Haas-Kogan DA
Cancer; 2019 Apr; 125(8):1357-1364. PubMed ID: 30602061
[TBL] [Abstract][Full Text] [Related]
11. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience.
Pondrom M; Bougeard G; Karanian M; Bonneau-Lagacherie J; Boulanger C; Boutroux H; Briandet C; Chevreau C; Corradini N; Coze C; Defachelles AS; Galmiche-Roland L; Orbach D; Piguet C; Scoazec JY; Vérité C; Willems M; Frebourg T; Minard V; Brugières L
Pediatr Blood Cancer; 2020 Sep; 67(9):e28486. PubMed ID: 32658383
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers.
Hettmer S; Archer NM; Somers GR; Novokmet A; Wagers AJ; Diller L; Rodriguez-Galindo C; Teot LA; Malkin D
Cancer; 2014 Apr; 120(7):1068-75. PubMed ID: 24382691
[TBL] [Abstract][Full Text] [Related]
14. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
15. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.
Diller L; Sexsmith E; Gottlieb A; Li FP; Malkin D
J Clin Invest; 1995 Apr; 95(4):1606-11. PubMed ID: 7706467
[TBL] [Abstract][Full Text] [Related]
16. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma.
Lynn M; Wang Y; Slater J; Shah N; Conroy J; Ennis S; Morris T; Betts DR; Fletcher JA; O'Sullivan MJ
Diagn Mol Pathol; 2013 Jun; 22(2):76-84. PubMed ID: 23628818
[TBL] [Abstract][Full Text] [Related]
17. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
Kashofer K; Regauer S
Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
[TBL] [Abstract][Full Text] [Related]
18. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
Skinner HD; Sandulache VC; Ow TJ; Meyn RE; Yordy JS; Beadle BM; Fitzgerald AL; Giri U; Ang KK; Myers JN
Clin Cancer Res; 2012 Jan; 18(1):290-300. PubMed ID: 22090360
[TBL] [Abstract][Full Text] [Related]
19. TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.
Maschietto M; Williams RD; Chagtai T; Popov SD; Sebire NJ; Vujanic G; Perlman E; Anderson JR; Grundy P; Dome JS; Pritchard-Jones K
PLoS One; 2014; 9(10):e109924. PubMed ID: 25313908
[TBL] [Abstract][Full Text] [Related]
20. MDM2 and CDK4 gene amplification in Ewing's sarcoma.
Ladanyi M; Lewis R; Jhanwar SC; Gerald W; Huvos AG; Healey JH
J Pathol; 1995 Feb; 175(2):211-7. PubMed ID: 7738717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
